Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.
The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine.
For investors, the significance extends far beyond Lilly alone.
The results reinforce a growing trend across oncology: precision medicine, biomarker-driven therapies, and targeted treatments continue producing some of the most dramatic outcomes in cancer care. As Wall Street digests Lilly's success, attention is increasingly shifting toward other companies with significant Phase 2 and Phase 3 oncology catalysts on the horizon.
Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store.
Eli Lilly: Raising the Oncology Standard
The LIBRETTO-432 trial enrolled patients with Stage IB-IIIA RET fusion-positive NSCLC following surgery or radiation.
Key findings included:
- 83% reduction in recurrence or death risk
- 92% event-free survival rate at 24 months versus 61% for placebo
- Strong consistency across patient subgroups
- Favorable safety profile generally consistent with prior studies
The results further validate RET as a critical biomarker alongside EGFR and ALK mutations in lung cancer and could accelerate adoption of comprehensive genomic testing across all stages of disease.
NeOnc Technologies
Among smaller-cap oncology companies, NeOnc Technologies (NASDAQ:NTHI) continues attracting investor attention due to multiple upcoming clinical catalysts focused on difficult-to-treat brain cancers.
Management recently highlighted several near-term milestones, including:
- Interim NEO100 data expected in the coming months
- FDA discussions regarding a potential registrational Phase 2 pathway for NEO212
- Ongoing development programs targeting central nervous system malignancies
The company has also reported insider purchases by senior leadership ahead of these anticipated milestones, often viewed by investors as a signal of management confidence. Recent updates indicate NTHI remains focused on advancing therapies for glioblastoma and other aggressive CNS cancers, with a delivery technology designed to penetrate the blood-brain barrier.
Olema Pharmaceuticals
Breast cancer remains one of the largest oncology markets globally, and Olema Pharmaceuticals (NASDAQ:OLMA) is advancing multiple clinical programs aimed at hormone receptor-positive disease.
Upcoming catalysts include:
- Initial clinical data from OP-3136
- Ongoing Phase 3 OPERA-02 study
- Continued advancement of palazestrant across multiple late-stage programs
With multiple shots on goal and Phase 3 studies underway, Olema remains firmly on many biotech investors' watchlists heading into the second half of 2026.
Pfizer
Pfizer (NYSE:PFE) remains a major oncology player with several important development programs moving through late-stage testing.
At ASCO 2026, the company is presenting updates across:
- Lung cancer
- Breast cancer
- Prostate cancer
- Colorectal cancer
- Multiple next-generation targeted therapies
Investors continue monitoring Pfizer's ability to expand existing oncology franchises while advancing new precision medicine candidates through development.
Why Oncology Catalysts Matter More Than Ever
Lilly's LIBRETTO-432 success serves as another reminder that breakthrough clinical data can dramatically reshape treatment standards, regulatory pathways, and company valuations.
As precision oncology continues evolving, companies with meaningful Phase 2 and Phase 3 readouts may attract increasing investor attention throughout 2026.
While clinical development always carries substantial risk, upcoming data from companies including Eli Lilly (NYSE:LLY), NeOnc Technologies Holdings (NASDAQ:NTHI), Olema Pharmaceuticals (NASDAQ:OLMA), and Pfizer (NYSE:PFE) are expected to remain firmly on investors' radar as the oncology catalyst calendar unfolds.
Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store.
Sources and Links
- https://investor.lilly.com
- https://www.nasdaq.com/press-release/neonc-technologies-holdings-inc-announces-300000-insider-purchases-nthi-stock
- https://www.nasdaq.com/press-release/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides
- https://www.nasdaq.com/press-release/bristol-myers-squibb-unveil-new-data-ascor-2026-demonstrating-strength-and-breadth
- https://www.nasdaq.com/press-release/pfizer-showcases-oncology-innovation-and-next-generation-pipeline-asco-2026-2026-04
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company's profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company's visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. For the full disclosure, please visit: https://go.247marketnews.com/nthi-disclosure/
For further information, please visit 247marketnews.com.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
